These mice were engrafted with HLA-matched human melanoma cells, and they showed that while anti-PD1 treatment only partially reduced tumor growth, the combination of anti-PD1 with targeted therapy receptor tyrosine kinase inhibitor (TKI) sunitinib or imatinib led to complete tumor regression associated with mast cell depletion. The gene discussed is PDCD1; the disease is melanoma.